alexa Sympathomimetic Recreational Drugs And Takotsubo Cardiomyopathy (TTC); Analysis From National Inpatient Survey (NIS) 2012-2014
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Joint Conference on 17th European Heart Disease and Heart Failure Congress and 2nd International Conference on Cardiovascular Medicine and Cardiac Surgery
March 15-17, 2017 London, UK

Samson Alliu
Maimonides Medical Center, USA
Posters & Accepted Abstracts: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880.C1.066
Background: Sympathomimetic recreational drugs (cocaine, amphetamines) causes’ decreased uptake of catecholamine causing sudden elevation in the levels of catecholamine (serotonin, epinephrine and norepinephrine). Takotsubo cardiomyopathy (TTC) is caused by a sudden elevation in the serum catecholamine. Given the similarity in the pathophysiology of TTC and pharmacodynamics of these drugs, it is unclear if TTC prevalence is different among this patient population. Objective: Aim of this study is to investigate if the prevalence of TTC is higher among patient that uses sympathomimetic drugs (cocaine, amphetamines) when compared to the general population. Methods: Among all the patients in the National Inpatient Sample database 2012-2014 (N=14,533,997), we identified patients using cocaine, amphetamine. Our outcome of interest was prevalence of TTC in this population. Logistic regression analysis was performed to assess the association between these recreational drugs and TTC. Using multivariate regression model, we adjusted for known confounders of cardiac morbidity and mortality; age, gender, race, insurance type, socioeconomic status, tobacco use, alcohol abuse, hyperlipidemia, diabetes, hypertension, renal failure, prior history of coronary artery disease and myocardial infarction. Results: Among our total sample, 0.95% (138,659) uses cocaine, 0.44% (63,773) uses amphetamine, 1.37% (1,98,504). TTC was diagnosed in 0.08% (12,070). There was no statistically significant difference in the odds of TTC among patient that uses cocaine (AOR 1.00 [0.78-1.26]) and amphetamine (1.00[0.71-1.42]). Overall, patients that were diagnosed with TTC were likely to be female (AOR 5.32 [5.04-5.62]), white (AOR 1.56[1.47-10.54]), history of hypertension (AOR 1.20[1.14-125], hyperlipidemia (AOR 1.50[1.44- 1.57]), smoking (AOR 1.41[1.33-1.48]) and increasing odds trends with age (AOR 12.78[10.71-15.25]). Conclusion: Despite the common pathway of catecholamine surge in TTC and sympathomimetic recreational drugs (cocaine and amphetamine), the prevalence of TTC is same among patients who use cocaine or amphetamine and the general population. However, female gender, white race, hypertension, hyperlipidemia, smoking and increasing age are risk factors for TTC.

Samson Alliu completed his Graduation at University of Alabama at Birmingham with an MPH in Epidemiology. He is currently pursuing his Residency in Internal Medicine at Maimonides Medical Center. His research interests are “Cardiovascular disease outcome research and risk factors”.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version